Literature DB >> 2693125

The activity of peptides of the endothelin family in various mammalian smooth muscle preparations.

C A Maggi1, S Giuliani, R Patacchini, P Rovero, A Giachetti, A Meli.   

Abstract

The activity of natural endothelins such as ET-1, ET-2, ET-3 and of sarafotoxin S6b (SRFTX) as compared to that of the C-terminal hexapeptide ET-(16-21) was investigated in several smooth muscle preparations in the presence of indomethacin, captopril, bestatin and thiorphan. In some tissues (rat thoracic aorta, guinea-pig ileum, human urinary bladder, renal pelvis or renal artery), ET-(16-21) had little if any agonist activity. In other preparations (guinea-pig bronchus, rat vas deferens, rabbit pulmonary artery) ET-(16-21) was a full agonist. The amidated form of ET-(16-21) was either inactive or less potent than ET-(16-21). These findings provide evidence that at least two receptors exist for peptides of the ET family; these receptors were termed ETA and ETB. ET-(16-21) is a full agonist at ETB receptors while being inactive or weakly active at ETA receptors. The free acid of tryptophan in position 21 plays a key role in the activity of these peptides at ETB receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2693125     DOI: 10.1016/0014-2999(89)90869-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

1.  Regional differences in the density and subtype specificity of endothelin receptors in rabbit urinary tract.

Authors:  J Latifpour; Y Fukumoto; R M Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

2.  Contraction and intracellular calcium-ion elevation of cultured human aortic smooth muscle cells by endothelin-1, vasoactive intestinal contractor (VIC) and the derivatives.

Authors:  A Iwashima; M Kobayashi; K Saida; H Kagamu; S Ohashi; M Arakawa; Y Mitsui
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Nov-Dec       Impact factor: 2.416

3.  Endothelin (16-21): biphasic effect and no desensitization on the guinea-pig isolated ileum.

Authors:  N Miasiro; C R Nakaie; A C Paiva
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

4.  Endothelin-1-induced activation of rat renal pelvic contractions depends on cyclooxygenase-1 and Rho kinase.

Authors:  Olaf Grisk; Martin Packebusch; Antje C Steinbach; Torsten Schlüter; Ulla C Kopp; Rainer Rettig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-09-22       Impact factor: 3.619

5.  Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.

Authors:  T D Warner; G H Allcock; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan.

Authors:  G G Mattera; A Eglezos; A R Renzetti; J Mizrahi
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

7.  Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens.

Authors:  S Télémaque; P D'Orléans-Juste
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

8.  Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat.

Authors:  S A Douglas; C R Hiley
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

9.  Differential effects of BQ-123 against endothelin-1 and endothelin-3 on the rat vas deferens: evidence for an atypical endothelin receptor.

Authors:  A Eglezos; P Cucchi; R Patacchini; L Quartara; C A Maggi; J Mizrahi
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  Structure-activity studies on endothelin (16-21), the C-terminal hexapeptide of the endothelins, in the guinea-pig bronchus.

Authors:  P Rovero; R Patacchini; C A Maggi
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.